Safety and efficacy of bilastine: A new H 1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria

Expert Opinion on Drug Safety

Volumn 10, Issue 5, 2011, Pages 779-793

  Church, Martin K ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

allergic rhinoconjunctivitis; bilastine; H 1 antihistamines; safety; urticaria

Indexed keywords

ALCOHOL; ANTIHISTAMINIC AGENT; BILASTINE; CETIRIZINE; GLYCOPROTEIN P; HISTAMINE; HYDROXYZINE; KETOCONAZOLE; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; FOOD INTAKE; HAY FEVER; NONHUMAN; REVIEW; SINGLE DRUG DOSE; URTICARIA;

ANIMALS; BENZIMIDAZOLES; CLINICAL TRIALS, PHASE I AS TOPIC; HISTAMINE H1 ANTAGONISTS; HUMANS; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHINITIS, ALLERGIC, SEASONAL; URTICARIA;

EID: 80052005071     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.604029     Document Type: Review

References (60)

1. Leurs R, Church MK, Taglialatela M. H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002;32:489-98
2. Bilastine SPC 2010. Summary of Product Characteristics for Bilastine 20 mg. Available from: Https://sinaem4. agemed.es/consaem/es pecialidad.do? metodo=verFichaWordPdf&codigo= 73027&formato =pdf&formulario=FICHAS [Last accessed 2 April 2011]
3. Emanuel MB. Histamine and the antiallergic antihistamines: A history of their discoveries. Clin Exp Allergy 1999;29(Suppl 3):1-11
4. Nicholson AN. Central effects of H1 and H2 antihistamines. Aviat Space Environ Med 1985;56:293-8
5. Meltzer EO. Comparative safety of H1 antihistamines. Ann Allergy 1991;67:625-33
6. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351:2203-17
7. Holgate ST, Canonica GW, Simons FE, et al. Consensus group on new-generation antihistamines (CONGA): Present status and recommendations. Clin Exp Allergy 2003;33:1305-24
8. Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010;126:466-76 Consensus regarding properties of an 'ideal' antihistamine.
9. Jauregizar N, de la Fuente L, Lucero ML, et al. Pharmacokinetic- pharmacodynamic modelling of the antihistaminic H1-effect of bilastine. Clin Pharmacokinet 2009;48:543-54
10. Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 2010;65(Suppl 93):1-13
11. Bailey DG. Fruit juice inhibition of uptake transport: A new type of food-drug interaction. Br J Clin Pharmacol 2010;70:645-55
12. Alejandro A, Lucero ML, Sainz L, Orjales A. Gastrointestinal metabolism of bilastine. In vitro study. XIII Congreso Nacional de la Sociedad Espanola de Quimica Terapeutica. Santiago de Compostela (Spain). 9 - 12 September 2003; Abstract P-74. Congress Abstracts Book. 2003:130
13. FAES FARMA S. A. June 2011. Available from: Http://www.faes.es/ faesfarma.lasso? LANG=en&FA=def90a960e136d7d [Last accessed 15 June 2011]
14. Sologuren A, Lucero ML, Valiente R, et al. Human mass balance with [14C]-bilastine following oral administration to healthy volunteers. Basic Clin Pharmacol Toxicol 2009;105(Suppl 1):106-7
15. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57
16. Zechnich AD, Hedges JR, Eiselt-Proteau D, Haxby D. Possible interactions with terfenadine or astemizole. West J Med 1994;160:321-5
17. Crean CS, Sologren A, Valiente R, McLaverty D. The drug-drug interaction of ketoconazole on bilastine pharmacokinetics. Basic Clin Pharmacol Toxicol 2007;101(Suppl 1):148-9
18. Takano M, Hasegawa R, Fukuda T, et al. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in caco-2 cells. Eur J Pharmacol 1998;358:289-94
19. Corcostegui R, Labeaga L, Innerarity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: Receptor selectivity and in vitro antihistaminic activity. Drugs R D 2005;6:371-84
20. Wolff S C, Brubaker K, Navratil T, et al. Evaluation of muscarinic receptor antagonism by antihistamines. Allergy 2007;62(Suppl 83):138
21. Garcia-Gea C, Martinez-Colomer J, Antonijoan RM, et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: A dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008;28:675-85
22. Corcostegui R, Labeaga L, Innerarity A, et al.In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R D 2006;7:219-31
23. Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res 2010;59:391-8
24. Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64:158-65
25. Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: A randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39:1338-47
26. Sologuren A, Valiente R, Crean C, McLaverty D. Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine. J Clin Pharmacol 2007;47:1198
27. Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: A multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65:516-28
28. Tashiro M, Kato M, Miyake M, et al. Dose dependency of brain histamine H1 receptor occupancy following oral administration of cetirizine hydrochloride measured using PET with [(11)C] doxepin. Hum Psychopharmacol 2009;24:540-8
29. Meltzer EO, Weiler JM, Widlitz MD. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis. J Allergy Clin Immunol 1996;97:617-26
30. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999;104:927-33
31. Salmun LM, Gates D, Scharf M, et al. Loratadine versus cetirizine: Assessment of somnolence and motivation during the workday. Clin Ther 2000;22:573-82
32. Mann RD, Pearce GL, Dunn N, Shakir S. Sedation with "non- sedating" antihistamines: Four prescription-event monitoring studies in general practice. BMJ 2000;320:1184-6
33. Tashiro M, Sakurada Y, Iwabuchi K, et al. Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004;44:890-900
34. Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: A double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002;32:133-9
35. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24
36. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 1999;36:179-94
37. Chen C, Hanson E, Watson JW, Lee JS. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003;31:312-18
38. Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27:866-71
39. Obradovic T, Dobson GG, Shingaki T, et al. Assessment of the first and second generation antihistamines brain penetration and role of P-glycoprotein. Pharm Res 2007;24:318-27
40. Burton PS, Crean C, Kagey M, Nielsen JW. Permeability characteristics of bilastine, a potent and selective H1 receptor antagonist, in caco-2 cells. AAPS J 2007;9(Suppl 2):2910
41. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001;46:27-43
42. Petri N, Tannergren C, Rungstad D, Lennernas H. Transport characteristics of fexofenadine in the caco-2 cell model. Pharm Res 2004;21:1398-404
43. Gonzalo A, Lucero ML. Identification of processes involved in bilastine bioavailability in rats. Drug Metab Rev 2008;40(Suppl 1):42-3
44. Morag N, Lucero ML, Orjales A. In vitro hepatic metabolism of [14C] bilastine. Drug Metab Rev 2007;39(Suppl 1):114
45. Richardson GS, Roehrs TA, Rosenthal L, et al. Tolerance to daytime sedative effects of H1 antihistamines. J Clin Psychopharmacol 2002;22:511-15
46. Verster JC, Volkerts ER. Antihistamines and driving ability: Evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol 2004;92:294-303
47. Garcia-Gea C, Clos S, Antonioli DA, et al. Crossover, randomised, double-blind, double-dummy, placebo and positive standard-controlled, unicenter clinical trial to assess the possible interaction on CNS effects between bilastine (20 mg and 80 mg) and alcohol (0.8 g/kg) after single simultaneous administration in healthy subjects. Basic Clin Pharmacol Toxicol 2006;99(Suppl 1):30
48. Conen S, Theunissen EL, Van Oers AC, et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2010; [Epub ahead of print]
49. Craft TM. Torsade de pointes after astemizole overdose. Br Med J (Clin Res Ed) 1986;292:660
50. Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993;269:1532-6
51. Woosley RL. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996;36:233-52
52. Polak S, Wisniowska B, Brandys J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. J Appl Toxicol 2009;29:183-206
53. Taglialatela M, Pannaccione A, Castaldo P, et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998;54:113-21
54. Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: Results of a thorough QT study (TQTS) with QT-concentration analysis. J Clin Pharmacol June 3 2011;DOI:10.1177/ 0091270011407191
55. ICH Harmonized Tripartite Guideline E14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. Available from: Http://www.ich. org/fileadmin/Public&Web-Site/ ICH-Products/Guidelines/Efficacy/E14/ Step4/E14-Guideline.pdf [Last accessed 2 April 2011]
56. Malik M, Hnatkova K, Schmidt A, Smetana P. Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol 2009;49:674-83
57. Takemasa H, Nagatomo T, Abe H, et al. Coexistence of hERG current block and disruption of protein trafficking in ketoconazole-induced long QT syndrome. Br J Pharmacol 2008;153:439-47
58. Montoro J, del Cuvillo A, Jauregui I, et al. Bilastine and the central nervous system: Incidence of somnolence [abstract 926]. XXX Congress of the European Academy of Allergology and Clinical Immunology. Istanbul (Turkey). Jun 11 - 15, 2011. Allergy 2011;66(Suppl 94):358
59. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2) LEN task force report. Allergy 2011;66:317-30
60. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: Management of urticaria. Allergy 2009;64:1427-43